Payment overview · 2025
General Payments
$412.09
24 reported records · 10 companies
Healthcare provider profile · identity verified
Anu Prasad Vellanki, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GRAMERCY, LA · NPI 1497746499
Verified facts
What the public records show
CMS Open Payments records show Anu Prasad Vellanki, MD received $412.09 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 541 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $172.01 | 41.7% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.21 | 15.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.62 | 10.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.16 | 8.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.22 | 4.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.57 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.33 | 3.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.59 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.33 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.05 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.09 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $148.50 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $78.78 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.21 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 541 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 253 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
130 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
541 | 106 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
179 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
114 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
253 | 59 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1179 | 334 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1152 | 160 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1063 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 1003 | 277 |
| Gabapentin | Gabapentin | 855 | 230 |
| Losartan Potassium | Losartan Potassium | 647 | 182 |
| Furosemide | Furosemide | 599 | 173 |
| Metformin Hcl | Metformin Hcl | 575 | 142 |
| Jardiance | Empagliflozin | 541 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 533 | 150 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 465 | 133 |
| Lisinopril | Lisinopril | 432 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 416 | 119 |
| Carvedilol | Carvedilol | 412 | 102 |
| Meloxicam | Meloxicam | 397 | 135 |
| Clopidogrel | Clopidogrel Bisulfate | 392 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 373 | 97 |
| Eliquis | Apixaban | 372 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 89 |
| Allopurinol | Allopurinol | 322 | 83 |
| Trazodone Hcl | Trazodone Hcl | 317 | 95 |
| Omeprazole | Omeprazole | 316 | 80 |
| Potassium Chloride | Potassium Chloride | 301 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 72 |
| Diclofenac Sodium | Diclofenac Sodium | 257 | 108 |
| Ozempic | Semaglutide | 253 | 59 |
| Methocarbamol | Methocarbamol | 250 | 97 |
| Finasteride | Finasteride | 244 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 72 |
| Tramadol Hcl | Tramadol Hcl | 214 | 77 |
| Prednisone | Prednisone | 203 | 97 |
| Donepezil Hcl | Donepezil Hcl | 201 | 40 |
| Sertraline Hcl | Sertraline Hcl | 185 | 44 |
| Simvastatin | Simvastatin | 185 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 180 | 62 |
| Mounjaro | Tirzepatide | 179 | 38 |
| Spironolactone | Spironolactone | 178 | 46 |
| Famotidine | Famotidine | 176 | 50 |
| Glimepiride | Glimepiride | 176 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 175 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 172 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 36 |
| Januvia | Sitagliptin Phosphate | 163 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 28 |
| Ezetimibe | Ezetimibe | 143 | 41 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 143 | 43 |
| Alendronate Sodium | Alendronate Sodium | 139 | 40 |
| Levetiracetam | Levetiracetam | 139 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 32 |
| Baclofen | Baclofen | 136 | 25 |
| Mirtazapine | Mirtazapine | 136 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 135 | 48 |
| Azithromycin | Azithromycin | 133 | 108 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 133 | 35 |
| Linzess | Linaclotide | 130 | 41 |
| Pregabalin | Pregabalin | 130 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 30 |
| Montelukast Sodium | Montelukast Sodium | 125 | 36 |
| Farxiga | Dapagliflozin Propanediol | 122 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 26 |
| Memantine Hcl | Memantine Hcl | 115 | 26 |
| Trulicity | Dulaglutide | 114 | 20 |
| Xarelto | Rivaroxaban | 114 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 113 | 46 |
| Alprazolam | Alprazolam | 105 | 30 |
| Symbicort | Budesonide/Formoterol Fumarate | 99 | 28 |
| Clonidine Hcl | Clonidine Hcl | 98 | 29 |
| Naproxen | Naproxen | 98 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 90 | 34 |
| Entresto | Sacubitril/Valsartan | 89 | 17 |
| Atenolol | Atenolol | 88 | 25 |
| Buspirone Hcl | Buspirone Hcl | 85 | 19 |
| Ibuprofen | Ibuprofen | 84 | 34 |
| Metformin Hcl Er | Metformin Hcl | 83 | 21 |
| Ketoconazole | Ketoconazole | 81 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 40 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 79 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | 24 |
| Nifedipine Er | Nifedipine | 70 | 24 |
| Lorazepam | Lorazepam | 69 | 11 |
| Warfarin Sodium | Warfarin Sodium | 69 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 22 |
| Folic Acid | Folic Acid | 66 | 24 |
| Cilostazol | Cilostazol | 65 | 15 |
| Nystatin | Nystatin | 63 | 31 |
| Cephalexin | Cephalexin | 62 | 51 |
| Amoxicillin | Amoxicillin | 61 | 45 |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 58 | 21 |
| Cefdinir | Cefdinir | 57 | 48 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 13 |
| Latanoprost | Latanoprost | 55 | 13 |
| Topiramate | Topiramate | 55 | 20 |
| Lactulose | Lactulose | 54 | 27 |
| Meclizine Hcl | Meclizine Hcl | 54 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 52 | 50 |
| Valsartan | Valsartan | 52 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 21 |
| Glipizide | Glipizide | 50 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 20 |
| Fluconazole | Fluconazole | 49 | 30 |
| Novolog Flexpen | Insulin Aspart | 48 | 14 |
| Propranolol Hcl | Propranolol Hcl | 48 | 11 |
| Risperidone | Risperidone | 48 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 22 |
| Bumetanide | Bumetanide | 46 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 11 |
| Celecoxib | Celecoxib | 40 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Colchicine | Colchicine | 37 | 19 |
| Methenamine Hippurate | Methenamine Hippurate | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Anastrozole | Anastrozole | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 26 |
| Levemir Flexpen | Insulin Detemir | 35 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | 13 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 13 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 12 |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 18 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | 12 |
| Etodolac | Etodolac | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 16 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | 11 |
| Ramipril | Ramipril | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Renvela | Sevelamer Carbonate | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.09 · 24 records | ABBVIE INC. | AREXVY, CAPLYTA, FREESTYLE LIBRE 3, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error